Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERITAS: Verteporfin + Triamcinolone vs Verteporfin + Pegaptanib in Wet AMD
NCT00242580Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2005
- Primary completion
- Jan 2008
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 3 trial of verteporfin, triamcinolone, pegaptanib sodium in exudative macular degeneration, sponsored by Novartis. Started Sep 2005; status: completed.
02
Drugs
verteporfintriamcinolonepegaptanib sodium
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00242580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242580.